VACCINES: STRENGTHENING LEADERSHIP

Roger Connor and Dr. Hal Barron
Cautionary statement regarding forward-looking statements

All outlooks, targets, ambitions and expectations regarding future performance and the dividend should be read together with the section “Basis of preparation, assumptions and cautionary statement” on pages 5-7 of our stock exchange announcement relating to an update to investors dated 23 June 2021 and the “Basis of preparation, assumptions and cautionary statement” and “Reporting definitions” slides at the end of this presentation.

This document contains statements that are, or may be deemed to be, “forward-looking statements”. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘aim, ‘ambition’, ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulation, the UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The reader should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the SEC. All readers, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate. The Group cautions investors that a number of important factors, including those in this document, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D ‘Risk Factors’ in the Group’s Annual Report on Form 20-F for 2020 and any impacts of the COVID-19 pandemic.

Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of Adjusted measures are used to report the performance of our business, which are non-IFRS measures. Adjusted results, CER and other non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. These measures are defined and reconciliations to the nearest IFRS measure are available in our first quarter 2021 earnings release and Annual Report on Form 20-F for FY 2020 and in the “Reporting definition” slide at the end of this presentation. GSK provides guidance and outlooks on an Adjusted results basis only, for the reasons set out in the “Reporting definition” slide at the end of this presentation.
Strengthening leadership in vaccines

High single digit % sales CAGR 2021-26

Global reach and commercial execution
World class manufacturing capability and scale

Industry-leading pipeline, FiC / BiC potential, 16 Phase 2/3 assets
Unrivalled portfolio and breadth of technology platforms
Advancing COVID solutions

5 planned new launches by 2026, including £multi-billion RSV opportunity

Doubling Shingrix revenues in 5 years
Ambition to double meningitis sales and flu sales in next 10 years

All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See basis of preparation and assumptions in Appendix. CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from the above.

Shingrix, meningitis and flu revenues from 2020 base
FiC First-in-Class; BiC Best-in-Class
Industry leading portfolio
High efficacy and protection

Extensive and highly diversified portfolio

Vaccines revenues 2020

*DTP family vaccines (Diptheria, Tetanus, Pertussis, Hib, Polio and Hepatitis B)
Industry leading pipeline
Largest number of mid/late-stage assets in areas of significant unmet medical need

<table>
<thead>
<tr>
<th>Company</th>
<th>Phase 2</th>
<th>Phase 3 / Registrational</th>
</tr>
</thead>
<tbody>
<tr>
<td>Company A</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>Company B</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>Company C</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Company D</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Company E</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Company F</td>
<td>3</td>
<td>1</td>
</tr>
</tbody>
</table>

**RSV**
177k hospitalisations, 14k deaths per year in 65+ adults annually in the US\(^1\)

**Meningitis**
1.2m cases of IMD annually with ~10% mortality rate

**Antimicrobial Resistance**
700k deaths annually & est. 8x increase within 30 years\(^2\)

**COVID-19**
~2bn cases and close to 3m deaths globally to date

---

Note: Includes Phase 2 and Phase 3 trials for non-cancer vaccines
Sources: Company websites and Clinicaltrials.gov (March 2021); Registration as reported on company websites (March 2021)

IMD Invasive Meningococcal Disease
Extensive technology platform portfolio across R&D
Unlocking the synergy between vaccines and specialty medicines

Protein +/- adjuvant  mRNA  Glycoconjugate  Viral vector  Monoclonal antibodies  Human genetics & functional genomics

Underpinned by our focus on the science of the immune system
mRNA: an important technology in our pipeline

Our differentiated mRNA approach to enable multivalent and combination vaccines

5’ and 3’ optimisation (CureVac)

Investing at pace and building capabilities

— mRNA research centre in Rockville (USA)
— >200 GSK mRNA scientists globally
— 6 clinical candidates in the next 4 years
— 2 assets in clinic within 12 months
  — COVID-19 booster; multi-valent, addressing emerging variants
  — Improved seasonal influenza with multi-antigen construct
  — Combination (COVID/Flu) under evaluation

— 10x higher immune response allowing for lower doses*
— Refrigerator-stable (2-8°C)

Further optimisation using modified bases

*preclinical data in animal models
Pipeline with multiple potential first- and/or best-in-class assets

Total number of candidates

- RSV/Pertussis combo
- Gonorrhea
- COVID 2nd Gen (CureVac)
- Klebsiella pneumoniae
- CMV
- Th HSV
- Varicella new strain (US)
- HPV NG
- mRNA seasonal Flu (CureVac)

- MenABCWY (2nd Gen)
- C. difficile*
- SAM (rabies model)*
- SAM (COVID-19 model)*
- RSV paediatric
- Therapeutic HBV*
- Malaria* (fractional dose)
- Shigella*
- COVID-19 (SK Bioscience)**
- S. aureus*

Next wave of entrants ('21/'22)**

Phase 1

- 9 assets
- Phase 2
- 6 assets
- Phase 3 / Registrational
- 10 assets

Potential for:

- 5 new launches by 2026
- 5 POCs by 2023
- 5 FTIH starts in 2021

Five new launches by 2026: RSV OA, RSV maternal, MenABCWY 1st gen, COVID-19 NG, MMR US
5 PoC by 2023: MenABCWY-7B 2nd gen, mRNA improved flu, RSV ped, Th HBV, Staph aureus
5 FTIH starts in 2021: COVID-19 NG, MenABCWY-7B 2nd gen, Klebsiella pneumonia, CMV, Varicella NS

*In-license or other alliance relationship with third party
**New wave of entrants exclude Global Health targets;
*GSK is contributing pandemic adjuvant to COVID-19 vaccines collaborations; **Ph2 registrational trial
Pipeline information updated June 2021
Key growth drivers: opportunities and investment priorities

Note: Bars are not at scale. All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See basis of preparation and assumptions in Appendix. CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from the above.

Illustrative
- Vaccines
- Specialty Medicines
- General Medicines

More than 5% CAGR
- Vaccines high single digit CAGR 2021-26
  - Shingrix – double revenues in 5 years
  - Meningitis – aim to double revenues in 10 years
  - RSV – £Multi-billion peak year sales
  - Flu – new strategy to double revenues in 10 years

2021
- Marketed assets
  - Shingrix
  - Meningitis
  - Dovato
  - Cabenuva
  - Zejula
  - Blenrep
  - Jemperli*
  - Benlysta
  - Nucala
  - Trelegy

2026
- Late-stage Pipeline
  - RSV
  - Cab ABCWY
  - Trelegy
  - Dolutegravir
  - Cervacix

Note: Bars are not at scale. All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See basis of preparation and assumptions in Appendix. CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from the above. Assets highlighted reflect major contributions to growth in period shown.

*Tesaro asset
Shingrix
Aim to double revenues in the next five years, protecting more than 100m adults

Major opportunity in US, China and beyond

- **Expanding** target populations: 50+ & 18+ (immunocompromised)
  - ~1.9bn 50+ people worldwide +
  - ~90m new people each year\(^1\)

[Flag] **US opportunity** ~100m 50+ people remain unvaccinated with Shingrix\(^2\)

[Flag] **Untapped China opportunity**

---

Gold standard for shingles prevention

- **Unprecedented high efficacy** >90% with proven 4-year duration of protection\(^3\)
- **Unconstrained supply** to support growth ambition
- **Geographic expansion**: 35 markets within next 3 years
- **Active life cycle management**
  - Label expansion: e.g., auto-immune disease
  - Fully liquid formulation

---

2. 121m 50+ people in US in 2021 based on ACIP recos. 24m vaccinated with Shingrix between 2017 and 2020 which leaves 97m yet to get vaccinated. 3. >80%, proven 8-year duration of protection [https://academic.oup.com/ofid/article/7/Supplement_1/S4/6057510](https://academic.oup.com/ofid/article/7/Supplement_1/S4/6057510)
Meningococcal franchise
Aim to double revenues in next decade, building on world-leading MenB vaccine

High growth opportunity through market expansion

— 1.2m cases of Invasive Meningococcal Disease (IMD) worldwide annually
  — Severe & devastating; ~10% mortality rate
  — Only ~17-25% receive MenB vaccine

Potential best-in-class portfolio & pipeline

— Market leader >50% share in a ~£2bn market with proven benefit backed by real world evidence

— Sustaining leadership & expanding market with Men ABCWY. In Phase 3 - 2024* launch

— World’s broadest coverage for all ages with improved convenience, 2nd Gen ABCWY in Phase 1-2

---

2. N Engl J Med 2020; 382:309-31; * Subject to regulatory approval
Meningitis ambition uses 2020 base.
RSV Older Adults: potential first- and best-in-class £multi-billion opportunity
Leveraging our proven adjuvant technology

One of the highest value, unmet need remaining in infectious diseases
Higher risk of severe outcomes than Influenza¹

<table>
<thead>
<tr>
<th></th>
<th>FLU</th>
<th>RSV</th>
</tr>
</thead>
<tbody>
<tr>
<td>% of patients hospitalised who stay ≥ 7 days¹</td>
<td>31%</td>
<td>43%</td>
</tr>
<tr>
<td>% of hospitalised patients admitted to intensive care¹</td>
<td>14%</td>
<td>18%</td>
</tr>
</tbody>
</table>

RSV OA: £5bn market opportunity**
>1bn 60+ people globally exposed to RSV annually

Most advanced RSV OA vaccine candidate in Phase 3 with best-in-class potential

- Pre-fusion F antigen combined with proven AS01 adjuvant in older adults
- Positive Phase 2 data:
  - Adjuvanted approach boosts neutralising antibodies ~10x with T-cell restoration similar in range to young adults
- FDA fast-track designation; launch in 2024*
- Planning for expanded adult indications & combinations with other adult vaccines

*subject to regulatory approval; **GSK estimate for total RSV OA market
RSV Maternal
Potential to provide broad protection to infants from first breath of life

One of the largest unmet needs in pediatrics

3.2m hospitalisations globally in under 5s
No. 1 cause of hospitalisation in under 5s
1.4m hospitalisations in infants aged under 6 months

More hospitalisations in first 2 years of life

*subject to regulatory approval

Polyclonal protection with potential game-changing RSV pertussis combo to follow

Differentiated approach with polyclonal passive immunity designed to offer broad protection across strains

Positive Phase 2 data through maternal antibody transfer to baby, launch 2024*

Potential protection of the mother & reduced transmission risk from mother to child

Developing next generation RSV and pertussis combination; FTIH 2022

US infant hospitalisation (in thousands)
Influenza
Innovating to deliver greater protection, new ambition to double revenues in next decade

Significant burden of disease remains¹

**Innovative technologies for superior efficacy**

1. Innovative plant-based protein adjuvanted vaccine for 65+ segment*, **Phase 3 data 2H 2023**

2. Next generation mRNA vaccine**; **Phase 3 data 2H 2025
   - Multi-antigen construct
   - Ambition of superiority vs standard of care
   - Potential for combinations with COVID & other respiratory IDs

3. Transformational universal flu vaccine & add-on mAb^ providing higher efficacy

Sub-optimal existing solutions

---


*GSK & Medicago collaboration agreement includes clinical supply of AS03 for development of an adjuvanted flu vaccine targeting the 65-plus age group; this vaccine is currently in phase I/II; phase III read out in 2H2023. The companies are in discussion regarding details of a commercialisation agreement; **in collaboration with CureVac; ^in collaboration with Vir.

IDs infectious diseases
Flu ambition uses 2020 base.
Strengthening leadership in vaccines

- High single digit % sales CAGR 2021-26
- Global reach and commercial execution
- World class manufacturing capability and scale
- Industry-leading pipeline, FiC / BiC potential, 16 Phase 2/3 assets
- Unrivalled portfolio and breadth of technology platforms
- Advancing COVID solutions
- 5 planned new launches by 2026, including £multi-billion RSV opportunity
- Doubling Shingrix revenues in 5 years
- Ambition to double meningitis sales and flu sales in next 10 years

All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See basis of preparation and assumptions in Appendix. CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from the above.

Shingrix, meningitis and flu revenues from 2020 base

FiC First-in-Class; BiC Best-in-Class
Basis of preparation, assumptions and cautionary statement

Assumptions relating to the 2021-2026 sales and adjusted operating profit growth outlooks, 2026 cash generated from operations outlook, 2031 sales ambition and 2021-2023 dividend expectations

In outlining the growth outlooks for the period 2021-2026, the 2026 cash generated from operations outlook, the 2031 sales ambition and the 2021-2023 dividend expectations (the “Relevant Statements”), GSK has made certain assumptions about the healthcare sector (including regarding possible governmental, legislative and regulatory reform), the different markets and competitive landscape in which it operates and the delivery of revenues and financial benefits from its current portfolio, its development pipeline of drugs and vaccines, its restructuring programmes and its plans for the separation of Consumer Healthcare, details of which are set out in this document.

GSK expects and assumes the next several years to be challenging for the healthcare industry with continued uncertainty related to the impact of the COVID-19 pandemic on adult vaccinations and continued pressure on pricing of pharmaceuticals. GSK assumes no premature loss of exclusivity for key products over the period. GSK also expects volume demand for its products to increase, particularly for Shingrix in the US, as healthcare systems are expected to return to normal following disruption from governments’ prioritisation of COVID-19 vaccination programmes and ongoing measures to contain the pandemic, and for Shingrix in China.

The assumptions underlying the Relevant Statements include: successful delivery of the ongoing and planned integration and restructuring plans and the planned demerger of Consumer Healthcare; the delivery of revenues and financial benefits from its current and development pipeline portfolio of drugs and vaccines (which have been assessed for this purpose on a risk-adjusted basis, as described further below); regulatory approvals of the pipeline portfolio of drugs and vaccines that underlie these expectations (which have also been assessed for this purpose on a risk-adjusted basis, as described further below); no material interruptions to supply of the Group’s products; no material mergers, acquisitions or disposals or other material business development transactions; no material litigation or investigation costs for the Company (save for those that are already recognised or for which provisions have been made); no share repurchases by the Company; and no change in the shareholdings in ViiV Healthcare.

The Relevant Statements also factor in all divestments and product exits announced to date as well as material costs for investment in new product launches and R&D. Pipeline risk-adjusted sales are based on the latest internal estimate of the probability of technical and regulatory success for each asset in development.

Notwithstanding the Relevant Statements, there is still uncertainty as to whether our assumptions, targets, outlooks expectations and ambitions will be achieved, including based on the other assumptions outlined above.

The statement that GSK estimates that certain assets in late-stage development have the potential to deliver peak year sales of more than £20 billion on a non-risk adjusted basis is an aggregation, across the relevant portfolio of assets, of the maximum sales that GSK considers might be achieved from each such asset (including from lifecycle innovation) in the year that that asset attains its highest sales level, in all cases before taking into account any risks that could impair GSK’s ability to reach that level of sales for that asset, including risks relating to technical and regulatory success, trial outcomes, launch dates and execution, exclusivity periods and the impact of changes in the market and healthcare landscape for that asset. The aggregation is of the peak year sales of each individual asset within the portfolio and not for one particular year. Accordingly, the statement of estimated non-risk adjusted potential peak year sales of the relevant assets in late-stage development does not comprise, is wholly different in nature to, and is subject to very significantly higher levels of uncertainty than the Relevant Statements. As such, while GSK does not expect to achieve the aggregate amount of those estimated non-risk adjusted peak year sales, a risk-adjusted assessment of sales of relevant assets during the relevant periods is (as stated above) taken into account, where relevant, within the Relevant Statements.

All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates (£1/$1.38, £1/€1.17, £1/Yen 152). 2021-2026 outlook refers to the 5 years to 2026 with 2021 as the base year.
Basis of preparation, assumptions and cautionary statement

Assumptions and cautionary statement regarding forward looking statements

The Group’s management believes that the assumptions outlined above are reasonable, and that the targets, outlooks, ambitions and expectations described in this document are achievable based on those assumptions. However, given the forward-looking nature of these assumptions, targets and expectations, they are subject to greater uncertainty, including potential material impacts if the above assumptions are not realised, and other material impacts related to foreign exchange fluctuations, macro-economic activity, the impact of outbreaks, epidemics or pandemics, such as the continued COVID-19 pandemic and ongoing challenges and uncertainties posed by the COVID-19 pandemic for businesses and governments around the world, changes in legislation, regulation, government actions or intellectual property protection, product development and approvals, actions by our competitors, and other risks inherent to the industries in which we operate.

This document contains statements that are, or may be deemed to be, “forward looking statements”. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘aim’, ‘ambition’, ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulation, the UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The reader should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the SEC. All readers, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate. The Group cautions investors that a number of important factors, including those in this document, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D ‘Risk Factors’ in the Group’s Annual Report on Form 20-F for 2020 and any impacts of the COVID-19 pandemic.

Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

Reporting definitions

A number of Adjusted measures are used to report the performance of our business, which are non-IFRS measures. Adjusted results, CER and other non-IFRS measures may be considered in addition to, but not as a substitute for or superior to, information presented in accordance with IFRS. These measures are defined and reconciliations to the nearest IFRS measure are available in our first quarter 2021 earnings release and Annual Report on Form 20-F for FY 2020.

GSK provides earnings guidance to the investor community on the basis of Adjusted results. This is in line with peer companies and expectations of the investor community, supporting easier comparison of the Group’s performance with its peers. GSK is not able to give guidance and outlooks for Total results, including Total Operating Profit and Total Operating Margin as it cannot reliably forecast certain material elements of the Total results, particularly the future fair value movements on contingent consideration and put options that can and have given rise to significant adjustments driven by external factors such as currency and other movements in capital markets. Therefore a reconciliation of the guidance for Adjusted results to equivalent guidance for Total results is not available without unreasonable effort.

Compound Annual Growth Rate (CAGR) is defined as the compound annual growth rate and shows the annualised average rate of revenue or profit growth between two given years, at constant currency, assuming growth takes place at an exponentially compounded rate.

Adjusted EBITDA is defined as Adjusted Earnings before interest and tax, depreciation and amortisation.
New GSK financial reporting considerations

IFRS income statement

Operating segments

- Commercial
  Revenue and Adjusted OP
- R&D
  Adjusted OP
- Corporate / other / adjusting items
  OP

Product Area Revenues

- Vaccines
- Specialty Medicines
- General Medicines

Revenue and Revenue by key product
Contact

GSK Investor Relations Team
+44 (0)20 8047 5000 or at
GSK.Investor-Relations@gsk.com